Antinociceptive activity of the new triple reuptake inhibitorNS18283 in a mouse model of chemotherapy‐induced neuropathic pain
Authors:
- 18 March 2015
- journal article
- research article
- Published by Wiley in European journal of pain
- Vol. 19 (3) , 322-333
Abstract
Background: Chronic neuropathic pain can lead to anxiety and depression. Drugs that block reuptake of serotonin, norepinephrine and/or dopamine are widely used to treat depression, and have emerged as useful drugs in the treatment of neuropathic pain. This study compared the acute antinociceptive effects ofNS18283, a novel triple monoamine reuptake inhibitor (MRI) with indatraline, venlafaxine and escitalopram in a mouse model of neuropathic pain.Method: Neuropathic pain‐like behaviours were induced in mice by repeated injections of oxaliplatin (OXA), and assessed using the von Frey hair test, the cold plate test and the thermal preference plate test. Anxio/depressive phenotype and antidepressant‐like properties of compounds were assessed by the novelty suppressed feeding test and the tail suspension test, respectively.Results: In vivomicrodialysis experiments showed that eachMRIincreased extracellular serotonin, norepinephrine and/or dopamine levels in the cingulate cortex, in agreement with their in vitro reuptake inhibitory properties. Indatraline (3 mg/kg) reversed the full repertoire ofOXA‐induced neuropathic hypersensitivity.NS18283 (10 mg/kg) reversedOXA‐induced mechano‐hypersensitivity and cold allodynia. Venlafaxine (16 mg/kg) and escitalopram (4 mg/kg) only reversed cold allodynia and mechano‐hypersensitivity, respectively. AllMRIsproduced antidepressant‐like activity in anxio/depressive phenotype ofOXAmice.Conclusions: Acute administration of drugs that enhance the activity of serotonin, norepinephrine and dopamine neurotransmission within nociceptive pathways may provide a broader spectrum of antinociception than dual or selective reuptake inhibitors in animal models of neuropathic pain. Whether similar observations would occur after repeated administration of such compounds in an attempt to simulate dosing in humans, or be compromised by dopaminergic‐mediated adverse effects warrants further investigation.Keywords
This publication has 74 references indexed in Scilit:
- Inter-examiner reliability of a proposed decision-making treatment based classification system for low back pain patientsManual Therapy, 2012
- Rapid synaptic potentiation within the anterior cingulate cortex mediates trace fear learningMolecular Brain, 2012
- The integration of negative affect, pain and cognitive control in the cingulate cortexNature Reviews Neuroscience, 2011
- Expression of the Dopaminergic D1 and D2 Receptors in the Anterior Cingulate Cortex in a Model of Neuropathic PainMolecular Pain, 2011
- Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodentsPharmacology Biochemistry and Behavior, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/DepressionNeuron, 2009
- Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbensNeuropharmacology, 2009
- Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance- and depression-related behaviourBritish Journal of Anaesthesia, 2007
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983